Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia

Phase 2 Completed 200 enrolled Beijing Northland Biotech. Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate whether intramuscular injections of NL003 into the calf is safe and effective in the treatment of critical limb ischemia

Timeline

Start: 2012-03
Primary completion: 2014-06
Completion: 2014-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NL003	Other / unclassified	4 mg	Intramuscular
Subject	NL003	Other / unclassified	6 mg	Intramuscular
Subject	NL003	Other / unclassified	8 mg	Intramuscular

Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia

Summary

Timeline

Drugs

Indications